Action CMPX COMPASS THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Compass Therapeutics, Inc.

Actions

CMPX

US20454B1044

Temps Différé Nasdaq
Autres places de cotation
 21:55:04 28/06/2024 		Varia. 5j. Varia. 1 janv.
1,14 USD -5,00 % Graphique intraday de Compass Therapeutics, Inc. +4,55 % -26,28 %
28/05 Compass Therapeutics, Inc. annonce des changements de PDG CI
28/05 Compass Therapeutics, Inc. annonce des changements au sein de sa direction CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compass Therapeutics : 2024 Proxy Supplemental
Compass Therapeutics Appoints Thomas Schuetz as CEO
Compass Therapeutics Announces CEO Transition
Compass Therapeutics, Inc. Announces CEO Changes
Compass Therapeutics, Inc. Announces Management Changes
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology Annual Meeting 2024
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Top Premarket Gainers
Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment
Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Compass Therapeutics : 2024 Proxy
Compass Therapeutics : Survey of CTX-009 Patient Selection Hypotheses Using Real World Biliary Tract Cancer Data
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CMPX
  4. Actualités Compass Therapeutics, Inc.
  5. Autres langues